Q-omics provides the consensus-scored INTS3 profile across patient tissues and cancer cell-line models. INTS3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, INTS3 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, INTS3 protein abundance shows 27,328 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight COAD, KICH, and LSCC as cancer lineages where INTS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INTS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INTS3 survival associations across molecular data types. INTS3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INTS3 RNA expression–survival associations across cancer types. High INTS3 expression shows unfavorable associations in COAD, KIRC, ACC, LGG and UVM, but favorable associations in HNSC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for INTS3 RNA expression.
This table summarizes INTS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 7. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for INTS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INTS3 shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, LIHC, HNSC and CHOL. The KICH box plot shows higher INTS3 RNA expression in normal versus tumor tissue (log2 FC = −1.513, t-test p < 0.001).
This table shows molecular features associated with INTS3 in patient tissues and cancer cell lines. In patient samples, INTS3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, INTS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
